Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04603443
Other study ID # NURR-003-19F
Secondary ID I01CX002022
Status Recruiting
Phase N/A
First received
Last updated
Start date June 1, 2021
Est. completion date December 31, 2024

Study information

Verified date March 2024
Source VA Office of Research and Development
Contact Miranda M Lim, MD PhD
Phone (503) 220-8262
Email miranda.lim@va.gov
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The most persistent and disabling postconcussive symptoms following mild traumatic brain injury (mTBI) are sleep disturbances and cognitive dysfunction, with few tractable interventions currently available. Here, a novel therapy will be tested consisting of dietary supplementation with branched chain amino acids (BCAA), based on the study team's previous preclinical work showing restoration of glutamate neurotransmitter balance in sleep and memory circuits. Supplementation with Amino acid Rehabilitative Therapy in TBI (SmART-TBI) is a randomized, placebo-controlled, double-blinded, exploratory clinical trial of BCAA intended to establish the feasibility, acceptability, and limited efficacy of long-term BCAA to improve sleep and cognition in Veterans with mTBI. These results will inform the optimal study design of a future, full-scale randomized controlled trial, including the identification of the proper dose and duration of BCAA to improve sleep and the potential subpopulations of Veterans with mTBI that may benefit the most.


Description:

Mild traumatic brain injury (mTBI) has impacted over 60% of all OEF/OIF Veterans over the past decade, and over 20% of these Veterans carry a diagnosis of postconcussion syndrome. Arguably the most disabling postconcussion symptoms are sleep-wake and cognitive disturbances. Sleep, cognitive function, and related symptoms often remain impaired >10-15 years following mTBI. Not only are these symptoms themselves exceedingly difficult to live with, but poor sleep and cognition also interfere with ongoing rehabilitation interventions, and prevent reintegration into civilian life and return to gainful employment. Most existing therapies for sleep-wake and cognitive dysfunction following mTBI are merely symptomatic, and they also suffer from low efficacy and/or patient acceptability. Thus, there is an urgent need to identify mechanism-based interventions for sleep and cognitive problems following mTBI, in order to facilitate optimal rehabilitation and functional outcomes. The study team's long-term goal is to implement a brain-bioactive pharmacological intervention to address sleep and cognitive disturbance in individuals with mTBI. The overall objective of this application, which represents the first step towards this goal, is to test the feasibility and limited efficacy of a highly promising therapy consisting of a dietary supplement, branched chain amino acids (BCAA; i.e., leucine, isoleucine, and valine), to treat sleep disturbances in individuals with mTBI. There is compelling scientific precedent and safety data to support the testing of BCAA therapy in Veterans with mTBI. Preliminary preclinical data has shown that the mechanism of action for BCAA, acting as a precursor to the excitatory neurotransmitter glutamate, restores the balance of excitation to inhibition within the dysfunctional brain circuits for both sleep and cognition in mTBI. With these data, the study team has also meticulously mapped the optimal dosing, duration, and route of administration in mice. Further, the study team now has pilot data from a double-blinded, placebo-controlled study showing that 3 weeks of dietary BCAA supplementation, but not placebo, significantly improved self-reported sleep in Veterans. Other research groups have used dietary BCAA supplementation in humans across multiple conditions at doses up to 60 grams/day and durations up to 12 months with few to no side effects. The central hypothesis is that BCAA dietary supplementation will improve sleep quality in Veterans with mTBI. As a first step towards testing this hypothesis, herein is proposed a long-term feasibility, acceptability, and limited efficacy study of BCAA's effects on sleep that will be randomized, placebo-controlled, and double-blinded. Veterans with mTBI will be randomly assigned to receive BCAA at 20, 40 or 60 grams/day per oral (PO) or a placebo (n=50 per group) for 12 weeks. Feasibility, acceptability, and limited efficacy outcomes based on sleep (e.g., self-report, continuous actigraphy, and overnight polysomnography) will be assessed. Results will inform the optimal study methodology and design for a future, full-scale randomized controlled trial, including the identification of the proper dose and duration of BCAA to improve sleep and the potential subpopulations of Veterans with mTBI that may be differentially affected by BCAA. This work will aos be used to generate hypotheses on the effect of BCAA on cognition and overall quality of life measures to inform future research.


Recruitment information / eligibility

Status Recruiting
Enrollment 200
Est. completion date December 31, 2024
Est. primary completion date December 31, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: - Be Veterans (male and female; any race; 18-65 years of age) - Be English speaking - Be accessible via phone - Be non-decisionally impaired - Attest to there being no chance of being or becoming pregnant during the study (if female) - Attest to no history of maple syrup urine disease or known family history of maple urine syrup disease - Have either a history of self-reported sleep disturbances, either as determined via the Insomnia Severity Index, Functional Outcomes of Sleep Questionnaire or Epworth Sleepiness Scale, clinical assessment, and/or a history of self-reported cognitive disturbance (e.g., poor memory, concentration, attention) - Not have an allergy to sucralose - Not be a shift worker (e.g. have worked night or rotating shifts more than twice in the past month) - Not have a diagnosis of amyotrophic lateral sclerosis - Not be currently supplementing their diet with branched chain amino acids - Not be starting another sleep intervention (e.g., positive airway pressure therapy for sleep apnea, sedative-hypnotic medication, or cognitive behavioral therapy for insomnia) during the study - if already engaged in another sleep intervention, this must be stable and not undergo further changes during the study - Meet diagnostic criteria for TBI using a validated clinical interview Exclusion Criteria: - Pregnancy or female trying to conceive - Under 18 years old - Known history of maple syrup urine disease - Dementia

Study Design


Intervention

Dietary Supplement:
Branched Chain Amino Acids
Isoleucine, Leucine, and Valine, 10g BID x 12 weeks
Branched Chain Amino Acids
Isoleucine, Leucine, and Valine, 20g BID x 12 weeks
Branched Chain Amino Acids
Isoleucine, Leucine, and Valine, 30g BID x 12 weeks
Protein Control
Protein placebo control - all amino acids except for BCAA, 10g BID x 12 weeks

Locations

Country Name City State
United States VA Portland Health Care System, Portland, OR Portland Oregon

Sponsors (3)

Lead Sponsor Collaborator
VA Office of Research and Development Children's Hospital of Philadelphia, Oregon Health and Science University

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Actiwatch Adherence Proportion of days with actiwatch worn (goal >70% days) Year 1
Primary Study Drug Adherence by drug accounting Proportion of study drug consumed within each timepoint assessed by drug accounting. Year 1
Primary Study drug adherence by sleep diary Proportion of study drug consumed assessed by sleep diary. Year 1
Primary Change in Monitoring of Side Effects Scale (MOSES) Change in Monitoring of side effects scale with emphasis on GI, neurological, psychiatric side effects. Range= 0-124, higher= more side effects. 12 weeks
Primary Study Drug Adherence by serum or sweat assay Proportion of study drug consumed assessed by serum or sweat assays of BCAA (goal >70% and >20% increase in levels. Year 1
Primary Patient satisfaction with overall study process Likert scale (1-5, higher= more satisfied) assessing satisfaction with consent process, staff, medication dispensing and regimen, devices/equipment, sleep study, questionnaires, cognitive testing, and overall experience of the study. 12 weeks
Primary Monitoring of Side Effects Scale (MOSES) Monitoring of side effects scale with emphasis on GI, neurological, psychiatric side effects. Range= 0-124, higher= more side effects. 4 weeks
Primary Change in Monitoring of Side Effects Scale (MOSES) Change in Monitoring of side effects scale with emphasis on GI, neurological, psychiatric side effects. Range= 0-124, higher= more side effects. 8 weeks
Primary Reasons for non-adherence Likert scale questions assessing response to statements including: "It upset my stomach", "I didn't have time", "it was too much to drink", "I didn't like the taste", "I didn't feel a benefit". Scale= 0-25, higher=agree more with statement. 4 weeks
Primary Change in Reasons for non-adherence Change in Likert scale questions assessing response to statements including: "It upset my stomach", "I didn't have time", "it was too much to drink", "I didn't like the taste", "I didn't feel a benefit". Scale= 0-25, higher=agree more with statement. 8 weeks
Primary Change in Reasons for non-adherence Change in Likert scale questions assessing response to statements including: "It upset my stomach", "I didn't have time", "it was too much to drink", "I didn't like the taste", "I didn't feel a benefit". Scale= 0-25, higher=agree more with statement. 12 weeks
Primary Recruitment Number of subjects consented of those eligible as descriptive percent Year 1
Primary Recruitment source Proportion of subjects recruited from various sources (clinical referral, flyers, ads, etc) Year 1
Primary Retention Number of completers out of the total number consented as descriptive statistic Year 1
Primary Retention by arm Proportion of drop out within each arm Year 1
Primary Incidence of non-participation Reasons for not participating after initial contact and before consent as descriptive percent. Year 1
Primary Screen Failures Number of subjects enrolled who were later found ineligible as a descriptive percent Year 1
Primary Screen Failures Number of subjects enrolled who were later found ineligible as a descriptive percent Year 2
Primary Screen Failures Number of subjects enrolled who were later found ineligible as a descriptive percent Year 3
Primary Screen Failures Number of subjects enrolled who were later found ineligible as a descriptive percent Year 4
Primary Incidence of non-participation Reasons for not participating after initial contact and before consent as descriptive percent. Year 2
Primary Incidence of non-participation Reasons for not participating after initial contact and before consent as descriptive percent. Year 3
Primary Incidence of non-participation Reasons for not participating after initial contact and before consent as descriptive percent. Year 4
Primary Retention by arm Proportion of drop out within each arm Year 2
Primary Retention by arm Proportion of drop out within each arm Year 3
Primary Retention by arm Proportion of drop out within each arm Year 4
Primary Retention Number of completers out of the total number consented as descriptive statistic Year 2
Primary Retention Number of completers out of the total number consented as descriptive statistic Year 3
Primary Retention Number of completers out of the total number consented as descriptive statistic Year 4
Primary Recruitment source Proportion of subjects recruited from various sources (clinical referral, flyers, ads, etc) Year 2
Primary Recruitment source Proportion of subjects recruited from various sources (clinical referral, flyers, ads, etc) Year 3
Primary Recruitment source Proportion of subjects recruited from various sources (clinical referral, flyers, ads, etc) Year 4
Primary Recruitment Number of subjects consented of those eligible as descriptive percent Year 2
Primary Recruitment Number of subjects consented of those eligible as descriptive percent Year 3
Primary Recruitment Number of subjects consented of those eligible as descriptive percent Year 4
Primary Study Drug Adherence by serum or sweat assay Proportion of study drug consumed assessed by serum or sweat assays of BCAA (goal >70% and >20% increase in levels. Year 2
Primary Study drug adherence by serum or sweat assay Proportion of study drug consumed assessed by serum or sweat assays of BCAA (goal >70% and >20% increase in levels. Year 3
Primary Study drug adherence by serum or sweat assay Proportion of study drug consumed assessed by serum or sweat assays of BCAA (goal >70% and >20% increase in levels. Year 4
Primary Study Drug Adherence by sleep diary Proportion of study drug consumed assessed by sleep diary. Year 2
Primary Study Drug Adherence by sleep diary Proportion of study drug consumed assessed by sleep diary. Year 3
Primary Study Drug Adherence by sleep diary Proportion of study drug consumed assessed by sleep diary. Year 4
Primary Study drug adherence by drug accounting Proportion of study drug consumed within each timepoint assessed by drug accounting. Year 2
Primary Study drug adherence by drug accounting Proportion of study drug consumed within each timepoint assessed by drug accounting. Year 3
Primary Study drug adherence by drug accounting Proportion of study drug consumed within each timepoint assessed by drug accounting. Year 4
Primary Actiwatch Adherence Proportion of days with actiwatch worn (goal >70% days) Year 2
Primary Actiwatch Adherence Proportion of days with actiwatch worn (goal >70% days) Year 3
Primary Actiwatch Adherence Proportion of days with actiwatch worn (goal >70% days) Year 4
See also
  Status Clinical Trial Phase
Terminated NCT03052712 - Validation and Standardization of a Battery Evaluation of the Socio-emotional Functions in Various Neurological Pathologies N/A
Recruiting NCT05503316 - The Roll of Balance Confidence in Gait Rehabilitation in Persons With a Lesion of the Central Nervous System N/A
Completed NCT04356963 - Adjunct VR Pain Management in Acute Brain Injury N/A
Completed NCT03418129 - Neuromodulatory Treatments for Pain Management in TBI N/A
Terminated NCT03698747 - Myelin Imaging in Concussed High School Football Players
Recruiting NCT05130658 - Study to Improve Ambulation in Individuals With TBI Using Virtual Reality -Based Treadmill Training N/A
Recruiting NCT04560946 - Personalized, Augmented Cognitive Training (PACT) for Service Members and Veterans With a History of TBI N/A
Completed NCT05160194 - Gaining Real-Life Skills Over the Web N/A
Recruiting NCT02059941 - Managing Severe Traumatic Brain Injury (TBI) Without Intracranial Pressure Monitoring (ICP) Monitoring Guidelines N/A
Recruiting NCT03940443 - Differences in Mortality and Morbidity in Patients Suffering a Time-critical Condition Between GEMS and HEMS
Recruiting NCT03937947 - Traumatic Brain Injury Associated Radiological DVT Incidence and Significance Study
Completed NCT04465019 - Exoskeleton Rehabilitation on TBI
Recruiting NCT04530955 - Transitioning to a Valve-Gated Intrathecal Drug Delivery System (IDDS) N/A
Recruiting NCT03899532 - Remote Ischemic Conditioning in Traumatic Brain Injury N/A
Suspended NCT04244058 - Changes in Glutamatergic Neurotransmission of Severe TBI Patients Early Phase 1
Completed NCT03307070 - Adapted Cognitive Behavioral Treatment for Depression in Patients With Moderate to Severe Traumatic Brain Injury N/A
Recruiting NCT04274777 - The Relationship Between Lipid Peroxidation Products From Traumatic Brain Injury and Secondary Coagulation Disorders
Withdrawn NCT04199130 - Cognitive Rehabilitation and Brain Activity of Attention-Control Impairment in TBI N/A
Withdrawn NCT05062148 - Fundamental and Applied Concussion Recovery Modality Research and Development: Applications for the Enhanced Recovery N/A
Withdrawn NCT03626727 - Evaluation of the Efficacy of Sodium Oxybate (Xyrem®) in Treatment of Post-traumatic Narcolepsy and Post-traumatic Hypersomnia Early Phase 1